Lymphoma Clinical Trials in North Carolina

Showing 461-480 of 554 trials

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory

Astellas Pharma Inc41 participantsStarted Jun 2007

Beverly Hills, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

COMPLETEDPhase 257 miles

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

NCT00359086

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.

Lymphoma

Mirati Therapeutics Inc.74 participantsStarted Aug 2006

Durham, North Carolina, United States • Houston, Texas, United States • Ottawa, Ontario, Canada +2 more locations

COMPLETEDPhase 265 miles

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

NCT01007292

The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.

Non-Hodgkin's Lymphoma

Astellas Pharma Inc43 participantsStarted Nov 2009

Columbus, Georgia, United States • Maywood, Illinois, United States • New York, New York, United States +16 more locations

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Lymphoma Trials in Other Cities

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Imexon for Relapsed Follicular and Aggressive Lymphomas

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Other Conditions in North Carolina